PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 (NCT05212103) | Clinical Trial Compass
By InvitationNot Applicable
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
Finland30 participantsStarted 2023-09-01
Plain-language summary
This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.
Who can participate
Age range18 Years – 100 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures.
* Diagnosis of metastatic melanoma and fit for immune checkpoint inhibitors or BRAF- and MEK inhibitors.
* Diagnosis of metastatic non-small cell lung cancer (NSCLC) (stage IV) and fit for immune checkpoint inhibitors and/or chemotherapy.
* Able and willing to give written informed consent and to comply with the study protocol.
Exclusion Criteria:
* Unsuitable for alloHSCT (AML), checkpoint inhibitors or BRAF- and MEK inhibitors (melanoma or checkpoint inhibitors and/or chemotherapy (NSCLC) according to the standard operating procedures.
* Unable or unwilling to comply with the study protocol for any reason.
* Evidence of significant uncontrolled concomitant diseases such as neurological, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the Investigator, would preclude patient participation
What they're measuring
1
68Ga-DOTA-Siglec-9 uptake in bone marrow and cancerous lesions